Eli Lilly and Company (BKK:LLY80)

Thailand · Delayed Price · Currency is THB

1.630

-0.040 (-2.40%)

At close: Dec 4, 2025

Market Cap	28.84T
Revenue (ttm)	1.93T
Net Income (ttm)	597.91B
Shares Out	n/a
EPS (ttm)	663.84
PE Ratio	48.24
Forward PE	32.00
Dividend	0.01 (0.38%)
Ex-Dividend Date	Nov 14, 2025

Volume	11,381,520
Average Volume	6,224,793
Open	1.670
Previous Close	1.670
Day's Range	1.630 - 1.690
52-Week Range	1.010 - 1.830
Beta	n/a
RSI	51.92
Earnings Date	Feb 6, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]

Industry Pharmaceutical Preparations

Founded 1876

Employees 47,000

Stock Exchange Stock Exchange of Thailand

Ticker Symbol LLY80

Full Company Profile

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD Financial Statements

News

There is no news available yet.